Pulmonary surfactant in patients with Pneumocystis pneumonia and acquired immunodeficiency syndrome

Critical Care Medicine

Volumn 34, Issue 9, 2006, Pages 2370-2376

  Schmidt, Reinhold ^a   Markart, Philipp ^a   Ruppert, Clemens ^a   Temmesfeld, Bettina ^b   Nass, Robert ^a   Lohmeyer, Jürgen ^a   Seeger, Werner ^a   Günther, Andreas ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute lung injury; Bronchoalveolar lavage; HIV; Pneumocystis carinii; Pneumocystis jiroveci; Pneumocystis pneumonia

Indexed keywords

FATTY ACID; LUNG SURFACTANT; PALMITIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPID; PROTEIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TRIACYLGLYCEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; FEMALE; HUMAN; LIPID ANALYSIS; LUNG ALVEOLUS SURFACE TENSION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; APOPROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; FEMALE; HIV INFECTIONS; HUMANS; INTENSIVE CARE UNITS; LIPIDS; LUNG; MALE; MIDDLE AGED; NEUTROPHILS; PNEUMONIA, PNEUMOCYSTIS; PROSPECTIVE STUDIES; PULMONARY GAS EXCHANGE; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL;

EID: 33747460337     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000234036.19145.52     Document Type: Article

References (40)

1. Thomas CF Jr, Limper AH: Pneumocystis pneumonia. N Engl J Med 2004; 350:2487-2498
2. Morris A, Creasman J, Turner J, et al: Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002; 166:262-267
3. Kovacs JA, Gill VJ, Meshnick S, et al: New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001; 286:2450-2460
4. Jain MK, Skiest DJ, Cloud JW, et al: Changes in mortality related to human immunodeficiency virus infection: Comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003; 36:1030-1038
5. Roblot F, Godet C, Le Moal G, et al: Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002; 21:523-531
6. Sowden E, Carmichael AJ: Autoimmune inflammatory disorders, systemic corticosteroids and Pneumocystis pneumonia: A strategy for prevention. BMC Infect Dis 2004; 4:42
7. Hawgood S, Clements JA: Pulmonary surfactant and its apoproteins. J Clin Invest 1990; 86:1-6
8. Veldhuizen R, Nag K, Orgeig S, et al: The role of lipids in pulmonary surfactant. Biochim Biophys Acta 1998; 1408:90-108
9. Hallman M, Spragg R, Harrell JH, et al: Evidence of lung surfactant abnormality in respiratory failure. J Clin Invest 1982; 70:673-683
10. Gregory TJ, Longmore WJ, Moxley MA, et al: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88:1976-1981
11. Günther A, Siebert C, Schmidt R, et al: Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996; 153:176-184
12. Atochina EN, Beck JM, Preston AM, et al: Enhanced lung injury and delayed clearance of Pneumocystis carinii in surfactant protein A-deficient mice: attenuation of cytokine responses and reactive oxygen-nitrogen species. Infect Immun 2004; 72:6002-6011
13. Escamilla R, Prevost MC, Hermant C, et al: Surfactant analysis during Pneumocystis carinii pneumonia in HIV-infected patients. Chest 1992; 101:1551-1562
14. Rose RM, Catalano PJ, Koziel H, et al: Abnormal lipid composition of bronchoalveolar lavage fluid obtained from individuals with AIDS-related lung disease. Am J Respir Crit Care Med 1994; 149:332-338
15. Hoffman AG, Lawrence MG, Ognibene FP, et al: Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest 1992; 102:1730-1736
16. Lohmeyer J, Friedrich J, Grimminger F, et al: Expression of mucosa-related integrin alphaEbeta7 on alveolar T cells in interstitial lung diseases. Clin Exp Immunol 1999; 116:340-346
17. Bernard GR, Artigas A, Brigham KL, et al: The American-European consensus conference on ARDS. Am J Respir Crit Care Med 1994; 149:818-824
18. Leroy O, Santre C, Beuscart C, et al: A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21:24-31
19. Veldhuizen R, Inchley K, Hearn SA, et al: Degradation of surfactant-associated protein B (SP-B) during in vitro conversion of large to small surfactant aggregates. Biochem J 1993; 95:141-147
20. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37:911-917
21. Günther A, Schmidt R, Feustel A, et al: Surfactant subtype conversion is related to loss of surfactant apoprotein B and surface activity in the large surfactant aggregates - Experimental and clinical studies. Am J Respir Crit Care Med 1999; 159:244-251
22. Schmidt R, Meier U, Yabut-Perez M, et al: Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome (ARDS) and severe pneumonia. Am J Respir Crit Care Med 2001; 163:95-100
23. Krämer HJ, Schmidt R, Günther A, et al: ELISA technique for quantification of surfactant protein B (SP-B) in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 1995; 152:1540-1544
24. Schmidt R, Steinhilber W, Ruppert C, et al: An ELISA technique for quantification of surfactant apoprotein (SP)-C in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 2002; 165:470-474
25. Griese M, Maderlechner N, Ahrens P, et al: Surfactant proteins A and D in children with pulmonary disease due to gastroesophageal reflux. Am J Respir Crit Care Med 2002; 165:1546-1550
26. Enhorning G: Pulsating bubble technique for evaluating pulmonary surfactant. J Appl Physiol 1977; 43:198-203
27. Seeger W, Günther A, Thede C: Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol 1992; 262:L286-L291
28. Veldhuizen RA, Welk B, Harbottle R, et al: Mechanical ventilation of isolated rat lungs changes the structure and biophysical properties of surfactant. J Appl Physiol 2002; 92:1169-1175
29. Gregory TJ, Steinberg KP, Spragg R, et al: Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155:1309-1315
30. Su TH, Natarajan V, Kachel DL, et al: Functional impairment of bronchoalveolar lavage phospholipids in early Pneumocystis carinii pneumonia in rats. J Lab Clin Med 1996; 127:263-271
31. Atochina EN, Beers MF, Scanlon ST, et al: Carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am J Physiol 2000; 278:L599-L609
32. Atochina EN, Beck JM, Scanlon ST, et al: Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. J Lab Clin Med 2001; 137:429-439
33. Phelps DS, Rose RM: Increased recovery of surfactant protein A in AIDS-related pneumonia. Am Rev Respir Dis 1991; 143:1072-1075
34. Sternberg RI, Whitsett JA, Hull WM, et al: Pneumocystis carinii alters surfactant protein A concentrations in bronchoalveolar lavage fluid. J Lab Clin Med 1995; 125:462-469
35. Phelps DS, Umstead TM, Rose RM, et al: Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat. Eur Respir J 1996; 9:565-570
36. Beers MF, Atochina EN, Preston AM, et al: Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice. J Lab Clin Med 1999; 133:423-433
37. Escamilla R, Prevost MC, Cariven C, et al: Bronchoalveolar lavage phospholipid abnormalities in HIV-infected patients. Eur Respir J 1993; 6:1301-1307
38. Rice WR, Singleton FM, Linke MJ, et al: Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat. J Clin Invest 1993; 92:2778-2782
39. Pesanti EL: Phospholipid profile of Pneumocystis carinii and its interaction with alveolar type II epithelial cells. Infect Immun 1987; 55:736-741
40. Wang Z, Foye A, Chang Y, et al: Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro. Am J Physiol 2005; 288:L1124-L1131